|
gptkbp:instanceOf
|
gptkb:synthetic_hormone
gptkb:drug
|
|
gptkbp:alsoKnownAs
|
gptkb:levothyroxine
|
|
gptkbp:ATCCode
|
H03AA01
|
|
gptkbp:bioavailability
|
40–80% (oral)
|
|
gptkbp:CASNumber
|
51-48-9
|
|
gptkbp:chemicalFormula
|
C15H11I4NO4
|
|
gptkbp:contraindication
|
gptkb:thyrotoxicosis
untreated adrenal insufficiency
|
|
gptkbp:discoveredBy
|
gptkb:Edward_Calvin_Kendall
|
|
gptkbp:drugInteraction
|
gptkb:warfarin
gptkb:cholestyramine
iron supplements
calcium supplements
antacids
|
|
gptkbp:eliminationHalfLife
|
about 7 days
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstSynthesized
|
1926
|
|
gptkbp:foundIn
|
gptkb:World_Health_Organization's_List_of_Essential_Medicines
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Levoxyl
gptkb:Eltroxin
gptkb:Euthyrox
gptkb:Levothroid
gptkb:Synthroid
gptkb:Thyrox
|
|
gptkbp:mechanismOfAction
|
binds to thyroid hormone receptors
|
|
gptkbp:meltingPoint
|
231°C
|
|
gptkbp:metabolism
|
gptkb:kidney
liver
|
|
gptkbp:pregnancyCategory
|
A (US)
|
|
gptkbp:producedBy
|
pharmaceutical synthesis
|
|
gptkbp:proteinBinding
|
high (>99%)
|
|
gptkbp:regulates
|
development
growth
metabolism
|
|
gptkbp:relatedTo
|
gptkb:triiodothyronine_(T3)
thyroid gland
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
anxiety
weight loss
insomnia
palpitations
hyperthyroidism
|
|
gptkbp:UNII
|
Q51BO43MG7
|
|
gptkbp:usedFor
|
hypothyroidism
thyroid hormone replacement
|
|
gptkbp:bfsParent
|
gptkb:T4
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
L-thyroxine
|